Lee Tai-Huang, Kuo Chia-Yu, Shen Yi-Wen, Kao Shih-Yu, Liu Yu-Wei, Lee Jui-Ying, Chuang Cheng-Hao, Lai Wei-An, Wu Chun-Chieh, Lee Mei-Shuan, Hung Jen-Yu, Chong Inn-Wen, Yang Chih-Jen
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
World J Surg Oncol. 2025 Aug 28;23(1):325. doi: 10.1186/s12957-025-03980-2.
Tumor spread through air spaces (STAS) and lymphovascular invasion (LVI) have been associated with poor prognosis in stage I non-small cell lung cancer (NSCLC). This study aimed to evaluate the prognostic significance of STAS and LVI, and to investigate the impact of adjuvant chemotherapy (ACT) on survival outcomes in this patient population.
A retrospective cohort study was conducted including 392 patients with pathological stage I NSCLC who underwent surgical resection at two Kaohsiung Medical University-affiliated hospitals between 2016 and 2019. Patients were stratified into three groups: STAS-positive without LVI (STAS + LVI-), STAS-positive with LVI (STAS + LVI+), and STAS-negative (STAS-). Survival outcomes were analyzed using Kaplan-Meier methods and Cox proportional hazards models. Associations between tumor size, STAS, and LVI were evaluated using chi-square tests.
STAS was identified in 101 patients (25.8%), of whom 20 (19.8%) also exhibited LVI. The prevalence of both STAS and LVI increased significantly with tumor size (p < 0.0001 for both). STAS positivity was independently associated with inferior recurrence-free survival (RFS) (hazard ratio [HR] = 2.33, p = 0.021). Overall, ACT did not significantly improve survival in STAS-positive patients (p = 0.63). However, among patients with concurrent STAS and LVI, a trend toward improved 5-year RFS was observed with ACT (54.5% vs. 44.4%; p = 0.43). In contrast, ACT was associated with significantly worse RFS in STAS-negative patients (p = 0.024).
STAS represents an independent adverse prognostic factor in stage I NSCLC, and conventional ACT appears to offer limited benefit in this group overall. Patients harboring both STAS and LVI may derive potential benefit from ACT, whereas STAS-negative patients may require careful evaluation to avoid overtreatment. These findings support the need for personalized, risk-adapted postoperative management strategies and warrant further prospective investigation.
肿瘤气腔播散(STAS)和脉管侵犯(LVI)与Ⅰ期非小细胞肺癌(NSCLC)的不良预后相关。本研究旨在评估STAS和LVI的预后意义,并探讨辅助化疗(ACT)对该患者群体生存结局的影响。
进行一项回顾性队列研究,纳入2016年至2019年间在高雄医学大学附属的两家医院接受手术切除的392例病理Ⅰ期NSCLC患者。患者被分为三组:STAS阳性无LVI(STAS+LVI-)、STAS阳性有LVI(STAS+LVI+)和STAS阴性(STAS-)。采用Kaplan-Meier法和Cox比例风险模型分析生存结局。使用卡方检验评估肿瘤大小、STAS和LVI之间的关联。
101例患者(25.8%)检测到STAS,其中20例(19.8%)也存在LVI。STAS和LVI的发生率均随肿瘤大小显著增加(两者p均<0.0001)。STAS阳性与无复发生存期(RFS)较差独立相关(风险比[HR]=2.33,p=0.021)。总体而言,ACT并未显著改善STAS阳性患者的生存(p=0.63)。然而,在同时存在STAS和LVI的患者中,观察到ACT有改善5年RFS的趋势(54.5%对44.4%;p=0.43)。相反,ACT与STAS阴性患者的RFS显著较差相关(p=0.024)。
STAS是Ⅰ期NSCLC的一个独立不良预后因素,传统ACT总体上对该组患者似乎益处有限。同时存在STAS和LVI的患者可能从ACT中获得潜在益处,而STAS阴性患者可能需要仔细评估以避免过度治疗。这些发现支持需要个性化、风险适应性的术后管理策略,并值得进一步进行前瞻性研究。